We focus on a number of topic areas identified by state health policy leaders as important to population health.
Keep up with news and updates from the Milbank Memorial Fund. Get the latest from thought leaders, including Christopher F. Koller, president of the Fund.
We publish The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to population health.
The Center for Evidence-based Policy at Oregon Health & Science University is a national leader in evidence-based decision making and policy design.
The Milbank Memorial Fund is an endowed operating foundation that publishes The Milbank Quarterly, commissions projects, and convenes state health policy decision makers on issues they identify as important to population health.
An endowed operating foundation that works to improve the health of populations by connecting leaders and decision makers with the best available evidence and experience
Aug 16, 2019
A new issue brief reviews existing Medicaid, Medicare, and private payer policies on home-based telehealth, and draws on stakeholder interviews, to give state policymakers a sense of the landscape. Read more
Jul 31, 2019 | Christopher F. Koller, President
Cruise down the East River in Manhattan and you may notice that the newest, largest, and most expensive high rises along the water belong to the medical-industrial complex, says Christopher F. Koller in his latest “View from Here” blog post. All over the US, in fact, many hospital administrators have become real estate moguls. Read more
In the first of a new Milbank Memorial Fund series, Research Into Practice, Jennifer Lloyd et al. discuss three Milbank Quarterly articles that address whether state government is an effective agent for transforming health care systems within the United States. The brief is the first in a series that aims to make the research findings from Milbank Quarterly studies and their policy implications more accessible to policymakers and practitioners.
A multidisciplinary journal of population health and health policy
August 2019 | Matthew Herder
Through its accelerated approval programs, the US Food and Drug Administration (FDA) has permitted several drugs with limited evidence of safety and effectiveness onto the market, provided that manufacturers agreed to carry out additional studies while the drugs were in clinical use. Read more
July 2019 | Audrey D. Zhang, Jason L. Schwartz, Joseph S. Ross
Conventional wisdom suggests that Food and Drug Administration (FDA) actions always reflect FDA advisory committee recommendations. But the FDA disagreed with 22% of its advisory committee recommendations over an 8-year period. Read more
View the current issue of the Quarterly
The Evolving Policy Landscape of Telehealth Services Delivered in the Home and Other Nonclinical Settings
August 14, 2019
Investing in Primary Care: A State-Level Analysis
July 19, 2019
In Support of Family Caregivers: A Snapshot of Five States
June 19, 2019
See all Publications
Get the Latest from the Milbank Memorial Fund